"NuVasive [NUVA]. It isn't an inexpensive stock, but it's a very early-stage stock with revenue growth around 60% being driven by new products. They have a product used in minimally invasive spine fusion surgery and they have a number of products under development that are potentially very interesting. One is an artificial disk product. There is nice potential upside if it works out. In the meantime, they have a very solid spinal-fusion business, which is driving all of the current estimates and growth rate."
http://online.barrons.com/article/SB119525667524396310.html?m...
This stock has a estimated 5-year growth rate of 31.1%.
$41.92 (12/13/07)
